We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

This study is currently recruiting participants.
Verified July 2017 by Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. )
Sponsor:
ClinicalTrials.gov Identifier:
NCT02208063
First Posted: August 4, 2014
Last Update Posted: July 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. )
  Purpose
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (RIE).

Condition Intervention Phase
Bacteremia Drug: Telavancin Drug: Vancomycin Drug: Daptomycin Drug: Synthetic penicillin Drug: Cefazolin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis

Resource links provided by NLM:


Further study details as provided by Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. ):

Primary Outcome Measures:
  • Clinical response (success or failure) [ Time Frame: Up to 8 weeks ]
    Clinical response (success or failure) for subjects with uncomplicated bacteremia receiving 2 to 4 weeks of treatment at test of cure (TOC) (38 [+/-2] days after randomization), for subjects with complicated bacteremia receiving 4 to 6 weeks of treatment at test of cure (TOC) (52 [+/-2] days after randomization), and for subjects with endocarditis receiving 6 weeks of treatment at test of cure (TOC) (52 [+/-2] days after randomization)


Secondary Outcome Measures:
  • Development of new metastatic foci of infection [ Time Frame: After Day 8 ]
  • Clearance of bacteremia [ Time Frame: Up to 8 weeks ]
    For subjects with a positive S. aureus blood culture on Day 1, time to all blood cultures negative for S. aureus for two days in succession


Estimated Enrollment: 248
Study Start Date: December 2014
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Telavancin
7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
Drug: Telavancin
Active Comparator: Standard of care
Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
Drug: Vancomycin Drug: Daptomycin
Other Name: Cubicin
Drug: Synthetic penicillin
Other Names:
  • Nafcillin
  • Oxacillin
  • Cloxacillin
Drug: Cefazolin

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older with at least one blood culture positive for S. aureus within 48 hours before randomization
  • At least one of the following signs or symptoms of bacteremia:

    • Temperature ≥ 38.0°C
    • WBC count > 10,000 or < 4,000 cells/µL or > 10% immature neutrophils (bands)
    • Tachycardia (heart rate > 90 bpm)
    • Tachypnea (respiratory rate > 20 breaths/min)
    • Hypotension (systolic blood pressure < 90 mmHg)
    • Signs or symptoms of localized catheter-related infection
  • At enrollment, subjects must have either 1) known right-sided infective endocarditis by Modified Duke's criteria 2) known complicated bacteremia, demonstrated as signs or symptoms of metastatic foci of S. aureus infection or 3) at least one risk factor for complicated bacteremia.

Exclusion Criteria:

  • Treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 60 hours within 7 days before randomization. EXCEPTION: Documented resistance to the prior systemic antibacterial therapy
  • Presence of an infection source that will not be managed or controlled within the first 3 days of study drug treatment
  • Presence of prosthetic cardiac valve or cardiac device (eg, implantable cardioverter defibrillator [ICD]), permanent pacemaker, or cardiac valve support ring)
  • Known or suspected left-sided infective endocarditis (LIE), by Modified Duke Criteria. NOTE: Right-sided infective endocarditis (RIE) is permitted
  • Known or suspected osteomyelitis or meningitis. NOTE: Evidence of metastatic complications related to the primary infection such as right-sided endocarditis, septic arthritis, septic pulmonary emboli are permitted. S. aureus pneumonia is permitted
  • Confirmed evidence (identification or gram stain) of a mixed polymicrobial infection with a Gram-negative pathogen that requires non-study antibiotic treatment with agent(s) that have activity against Gram-negative pathogens
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02208063


Contacts
Contact: Roger Kohler 650-808-6000 RKohler@theravance.com
Contact: Mia Elliott 650-808-6000 MElliott@theravance.com

Locations
United States, Ohio
Remington-Davis Clinical Research Recruiting
Columbus, Ohio, United States, 43215
Contact: Ian Baird, MD    614-487-2560    JBotte@remdavis.com   
Contact: Jennifer Botte, BS, RN, CCRC    (614) 487-2560    JBotte@remdavis.com   
Sponsors and Collaborators
Theravance Biopharma R & D, Inc.
Investigators
Study Director: Bibiana Castaneda, MD Theravance Biopharma R & D, Inc.
  More Information

Responsible Party: Theravance Biopharma R & D, Inc.
ClinicalTrials.gov Identifier: NCT02208063     History of Changes
Other Study ID Numbers: 0112
First Submitted: July 31, 2014
First Posted: August 4, 2014
Last Update Posted: July 21, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. ):
Bacteremia
Staphylococcus aureus

Additional relevant MeSH terms:
Bacteremia
Bacterial Infections
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Vancomycin
Cefazolin
Daptomycin
Penicillins
Telavancin
Anti-Bacterial Agents
Anti-Infective Agents